Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 23: 1245-1249, 1977;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pera, M. F.
Right arrow Articles by Harder, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pera, M. F., Jr
Right arrow Articles by Harder, H. C.

Clinical Chemistry, Vol 23, 1245-1249, Copyright © 1977 by American Association for Clinical Chemistry

Analysis for platinum in biological material by flameless atomic absorption spectrometry

MF Pera Jr and HC Harder

A method for determining platinum in biological materials by flameless atomic absorption spectrometry has been developed for use in pharmacological studies of platinum antitumor compounds. Tissue digests are analyzed in a heated graphite atomizer, with use of background correction and ramp temperature charring. We have overcome problems of apparent loss of platinum in Pt-supplemented tissue samples with time and of difficulty in analyzing tissue lipid. The validity of the assay was verified by injecting rats with radiolabeled cis- dichlorodiammineplatinum (II), then measuring platinum in tissues by gamma scintillation spectrometry and flameless atomic absorption spectrometry. Correlation between the two methods was excellent. The limit of the assay in its present form is about 0.1 migrogram/gram of wet tissue.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Cancer Res.Home page
B. Nakata, Y. Mitachi, A. Tsuji, S. Yamamitsu, K. Hirata, T. Shirasaka, and K. Hirakawa
Combination Phase I Trial of a Novel Oral Fluorouracil Derivative S-1 with Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902)
Clin. Cancer Res., March 1, 2004; 10(5): 1664 - 1669.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Viale, M. O. Vannozzi, I. Pastrone, M. A. Mariggiò, A. Zicca, A. Cadoni, S. Cafaggi, G. Tolino, G. Lunardi, D. Civalleri, et al.
Reduction of Cisplatin Nephrotoxicity by Procainamide: Does the Formation of a Cisplatin-Procainamide Complex Play a Role?
J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 829 - 836.
[Abstract] [Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
G. B. Ratto, S. Toma, D. Civalleri, G. C. Passerone, M. Esposito, D. Zaccheo, M. Canepa, P. Romano, R. Palumbo, F. De Cian, et al.
ISOLATED LUNG PERFUSION WITH PLATINUM IN THE TREATMENT OF PULMONARY METASTASES FROM SOFT TISSUE SARCOMAS
J. Thorac. Cardiovasc. Surg., September 1, 1996; 112(3): 614 - 622.
[Abstract] [Full Text]

Home page
 Arch Intern MedHome page
A. A. Nanji, N. Z. Mikhael, and D. J. Stewart
Increase in Serum Uric Acid Level Associated With Cisplatin Therapy: Correlation With Liver but Not Kidney Platinum Concentrations
Arch Intern Med, November 1, 1985; 145(11): 2013 - 2014.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1977 by the American Association for Clinical Chemistry.